Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian CancerGlobeNewswire (press release)LAWRENCEVILLE, N.J., Nov. 13, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ:CLSN), an oncology drug dev… Continue reading
Targeted OncologyExpert Discusses Ongoing Immunotherapy Research in CRCTargeted OncologyThey are very responsive to immunotherapies. In fact, we have seen FDA approvals of pembrolizumab for patients with MSI-H cancers, as well as nivolumab for MSI-H … Continue reading
R & D Magazine |
What’s Next For CAR T: The Potential of Engineering Immune Cells to Treat Cancer
R & D Magazine CAR T-cell therapy is created by collecting a patient’s T-cells, genetically modifying them to fight cancer, and then infusing them back into the patient. The first therapy in this class, tisagenlecleucel (Kymriah), was FDA approved in August 2017 in … Researchers Build a Cancer Immunotherapy Without Immune CellsThe Scientist |
OncLive |
Questions Remain With CAR–T’s, Checkpoints in Hematologic Malignancies
OncLive Despite major progress with chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors in hematologic malignancies, questions remain regarding the use of these therapies in this landscape, according to Leo I. Gordon, MD. |
William & Mary News |
William & Mary team wins First Runner-Up position in iGEM competition
William & Mary News Each year iGEM hosts the largest synthetic–biology competition in the world, a months-long, student-driven projects involving biology, mathematics, chemistry and engineering. William & Mary’s team also won two special awards, one for Best Innovation in … |